Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junmin Chen

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
Signal Transduction and Targeted Therapy|September 3, 2024
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 studyZhiyong Zeng, Apeng Yang, Jingke Yang, et al.
American Journal of Hematology|June 23, 2026
A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and PrognosisJing Li, Chenqi Yu, Jinghua Wang, et al.
Journal of Hematology & Oncology|May 9, 2023
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumorsYuanyuan Zhao, Yuxiang Ma, Aimin Zang, et al.
Innovation (Cambridge (Mass.))|May 14, 2023
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III studyHuijuan Zhong, Shu Cheng, Xi Zhang, et al.
Haematologica|April 10, 2025
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized studyHuijuan Zhong, Shu Cheng, Jie Xiong, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
Signal Transduction and Targeted Therapy|September 3, 2024
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 studyZhiyong Zeng, Apeng Yang, Jingke Yang, et al.
American Journal of Hematology|June 23, 2026
A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and PrognosisJing Li, Chenqi Yu, Jinghua Wang, et al.
Journal of Hematology & Oncology|May 9, 2023
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumorsYuanyuan Zhao, Yuxiang Ma, Aimin Zang, et al.
Innovation (Cambridge (Mass.))|May 14, 2023
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III studyHuijuan Zhong, Shu Cheng, Xi Zhang, et al.
Haematologica|April 10, 2025
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized studyHuijuan Zhong, Shu Cheng, Jie Xiong, et al.
Pageof 14